Table 4.
Triggers to treatment used in patients under Active Surveillance
| Publication | Gleason Score on repeat biopsy | Positive cores | % cancer involvement per single core | % positive biopsy cores | PSAdt cT (years) | PSAv (ng/ml/year) | cT |
|---|---|---|---|---|---|---|---|
| Dall’Era [11] | Progression | - | - | - | - | >0.75 | - |
| Tosoian [18] | >6 | >2 | >50 | - | - | - | - |
| Ercole [13] | Progression | Increase | Increase | - | - | - | Upstage |
| Klotz [14] | ≥4 | - | - | - | 3 | - | - |
| Ischia [15] | Progression | - | - | - | - | - | Upstage |
| Thomsen [16] | ≥3 + 4 | >3 | - | - | 3 | - | Upstage |
| Selvadurai [17] | ≥4 + 3 | - | - | >50 | - | >1 | - |
cT clinical tumour category, PSAdt prostate-specific antigen doubling time, PSAv PSA velocity